Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website; (3) the federal government Internet portal; or (4) a web search conducted using a commercial search engine such as
Accession Number ADA570968
Title Novel RNA Helicase Inhibitor to Treat Breast Cancer.
Publication Date Aug 2012
Media Count 6p
Personal Author V. Raman Y. Kato
Abstract In this funding cycle, we concentrated on encapsulating NZ51 into nanoparticles that are biocompatible and biodegradable. Earlier, we had reported that we were successful in preparing PLGA nanoparticles loaded with GdDTPA -BOA and superparamagnetic iron oxide (SPIO) nanoparticles. Based on that technology, we initiated experiments to load PLGA nanoparticles with NZ51. After a series of experiments, we concluded that there was significant variation from batch to batch preparation and we have to refine the technology used. Currently, we are attempting to encapsulate the RNA helicase inhibitor into a different nanoparticle, such as PLGA nanoparticles composed of low molecular weight copolymers, or nanoparticles composed of chitosan derivatives, with the goals of achieving a faster release resulting in increased efficacy for breast cancer treatment. Also, we are in the process to determine why the different batches made have different aggregation properties in mouse plasma. Furthermore, we are attempting to encapsulate a different DDX3 inhibitor into PLGA nanoparticle to evaluate if the chemical structure of NZ51 is in anyway interfering with the formulation and utility in in vivo experiments.
Keywords Batch processing
Breast cancer
In vivo analysis
Mammary glands
Molecular structure
Molecular weight
Ribonucleic acids

Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
57F - Cytology, Genetics, & Molecular Biology
Corporate Author Johns Hopkins Univ., Baltimore, MD.
Document Type Technical report
Title Note Annual rept. 1 Aug 2011-31 Jul 2012.
NTIS Issue Number 1315
Contract Number W81XWH-10-1-0603

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader